Targeting subcellular localization through the polo-box domain: Non-ATP competitive inhibitors recapitulate a PLK1 phenotype

Molecular Cancer Therapeutics

Volumn 11, Issue 8, 2012, Pages 1683-1692

  McInnes, Campbell ^a   Estes, Kara ^a,e   Baxter, Merissa ^a   Yang, Zhengguan ^a   Farag, Doaa Boshra ^b   Johnston, Paul ^c   Lazo, John S ^c,f   Wang, Jianjun ^d   Wyatt, Michael D ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MISR INTERNATIONAL UNIVERSITY   (Egypt)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Physicians Choice Laboratory Services   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; PEPTIDE DERIVATIVE; POLO LIKE KINASE 1; POLO LIKE KINASE 1 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CENTROSOME; CONTROLLED STUDY; DRUG DESIGN; DRUG TARGETING; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME LOCALIZATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE;

APOPTOSIS; CDC25 PHOSPHATASES; CELL CYCLE PROTEINS; HELA CELLS; HUMANS; INTRACELLULAR SPACE; MITOSIS; MOLECULAR DOCKING SIMULATION; PEPTIDES; PHENOTYPE; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84864871913     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0006-T     Document Type: Article

References (39)

1. Xie S, Xie B, Lee MY, Dai W. Regulation of cell cycle checkpoints by polo-like kinases. Oncogene 2005;24:277-86. (Pubitemid 40188608)
2. McInnes C, Wyatt MD. PLK1 as an oncology target: current status and future potential. Drug Discov Today 2011;16:619-25.
3. Yuan J, Hoerlin A, Hock B, Stutte HJ, Ruebsamen-Waigmann H, Strebhardt K. Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol 1997;150:1165-72. (Pubitemid 27152634)
4. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997;14:543-9. (Pubitemid 27090956)
5. Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 1999;15:687-92.
6. Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, et al. Polo-like kinase I is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004;60:240-5. (Pubitemid 38971835)
7. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003;94:148-52. (Pubitemid 36575873)
8. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr., Kinzler KW, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 2009;106:3964-9.
9. McKenzie L, King S, Marcar L, Nicol S, Dias SS, Schumm K, et al. p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle 2010;9:4200-12.
10. Elez R, Piiper A, Kronenberger B, Kock M, Brendel M, Hermann E, et al. Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene 2003;22:69-80. (Pubitemid 36152885)
11. Spankuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmuller M, et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002;21:3162-71. (Pubitemid 34548087)
12. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008;26:5504-10.
13. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008;26:5511-7.
14. Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007;17:304-15.
15. Yang Z, Waldman AS, Wyatt MD. DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol 2008;76:987-96.
16. Wang Q, Xie S, Chen J, Fukasawa K, Naik U, Traganos F, et al. Cell cycle arrest and apoptosis induced by human Polo-like kinase 3 is mediated through perturbation of microtubule integrity. Mol Cell Biol 2002;22:3450-9. (Pubitemid 34453984)
17. Yang Y, Bai J, Shen R, Brown SA, Komissarova E, Huang Y, et al. Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. Cancer Res 2008;68:4077-85.
18. Xu D, Yao Y, Jiang X, Lu L, Dai W. Regulation of PTEN stability and activity by PLK3. J Biol Chem 2010;285:39935-42.
19. Yun SM, Moulaei T, Lim D, Bang JK, Park JE, Shenoy SR, et al. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol 2009;16:876-82.
20. Elia AE, Cantley LC, Yaffe MB. Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science 2003;299:1228-31. (Pubitemid 36237463)
21. Elia AE, Rellos P, Haire LF, Chao JW, Ivins FJ, Hoepker K, et al. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the polo-box domain. Cell 2003;115:83-95. (Pubitemid 37255320)
22. Garcia-Alvarez B, de Carcer G, Ibanez S, Bragado-Nilsson E, Montoya G. Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization. Proc Natl Acad Sci U S A 2007;104:3107-12. (Pubitemid 46364121)
23. Reindl W, Yuan J, Kramer A, Strebhardt K, Berg T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 2008;15:459-66. (Pubitemid 351645109)
24. Watanabe N, Sekine T, Takagi M, Iwasaki J, Imamoto N, Kawasaki H, et al. Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem 2009;284:2344-53.
25. van Vugt MATM, van de Weerdt BCM, Vader G, Janssen H, Calafat J, Klompmaker R, et al. Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem 2004;279:36841-54. (Pubitemid 39129033)
26. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17:316-22. (Pubitemid 46241881)
27. Liu F, Park JE, Qian WJ, Lim D, Scharow A, Berg T, et al. Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. ACS Chem Biol 2012;7:805-10.
28. Liu F, Park JE, Qian WJ, Lim D, Graber M, Berg T, et al. Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Nat Chem Biol 2011;7:595-601.
29. Kanda T, Sullivan KF, Wahl GM. Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells. Curr Biol 1998;8:377-85. (Pubitemid 28173996)
30. Li Q, Huang Y, Xiao N, Murray V, Chen J, Wang J. Real time investigation of protein folding, structure, and dynamics in living cells. Methods Cell Biol 2008;90:287-325.
31. Jang Y-J, Lin C-Y, Ma S, Erikson RL. Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc Natl Acad Sci U S A 2002;99:1984-9. (Pubitemid 34169001)
32. Lowery DM, Lim D, Yaffe MB. Structure and function of Polo-like kinases. Oncogene 2005;24:248-59. (Pubitemid 40188605)
33. Andrews MJ, Kontopidis G, McInnes C, Plater A, Innes L, Cowan A, et al. REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors. Chembiochem 2006;7:1909-15. (Pubitemid 44893525)
34. Strebhardt K. Multifaceted polo-like kinases: drug targets and anti-targets for cancer therapy. Nat Rev 2010;9:643-60.
35. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321-30.
36. Qian Y-W, Erikson E, Li C, Maller JL. Activated polo-like kinase Plx1 is required at multiple points during mitosis in Xenopus laevis. Mol Cell Biol 1998;18:4262-71. (Pubitemid 28287949)
37. Seong YS, Kamijo K, Lee JS, Fernandez E, Kuriyama R, Miki T, et al. A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J Biol Chem 2002;277:32282-93. (Pubitemid 34969045)
38. Liao C, Park JE, Bang JK, Nicklaus MC, Lee KS. Exploring potential binding modes of small drug-like molecules to the polo-box domain of human polo-like kinase 1. ACS Med Chem Lett 2010;1:110-4.
39. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-48.